Search

Your search keyword '"Ji, Linong"' showing total 1,087 results
Start Over Author "Ji, Linong" Search Limiters Full Text
1,087 results on '"Ji, Linong"'

1. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

Author

Mann, Johannes F. E., Rossing, Peter, Bakris, George, Belmar, Nicolas, Bosch-Traberg, Heidrun, Busch, Robert, Charytan, David M., Hadjadj, Samy, Gillard, Pieter, Górriz, José Luis, Idorn, Thomas, Ji, Linong, Mahaffey, Kenneth W., Perkovic, Vlado, Rasmussen, Søren, Schmieder, Roland E., Pratley, Richard E., and Tuttle, Katherine R.

Published
2024
Full Text
View/download PDF

3. A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

Author

Klonoff, David C, Wang, Jing, Rodbard, David, Kohn, Michael A, Li, Chengdong, Liepmann, Dorian, Kerr, David, Ahn, David, Peters, Anne L, Umpierrez, Guillermo E, Seley, Jane Jeffrie, Xu, Nicole Y, Nguyen, Kevin T, Simonson, Gregg, Agus, Michael SD, Al-Sofiani, Mohammed E, Armaiz-Pena, Gustavo, Bailey, Timothy S, Basu, Ananda, Battelino, Tadej, Bekele, Sewagegn Yeshiwas, Benhamou, Pierre-Yves, Bequette, B Wayne, Blevins, Thomas, Breton, Marc D, Castle, Jessica R, Chase, James Geoffrey, Chen, Kong Y, Choudhary, Pratik, Clements, Mark A, Close, Kelly L, Cook, Curtiss B, Danne, Thomas, Doyle, Francis J, Drincic, Angela, Dungan, Kathleen M, Edelman, Steven V, Ejskjaer, Niels, Espinoza, Juan C, Fleming, G Alexander, Forlenza, Gregory P, Freckmann, Guido, Galindo, Rodolfo J, Gomez, Ana Maria, Gutow, Hanna A, Heinemann, Lutz, Hirsch, Irl B, Hoang, Thanh D, Hovorka, Roman, Jendle, Johan H, Ji, Linong, Joshi, Shashank R, Joubert, Michael, Koliwad, Suneil K, Lal, Rayhan A, Lansang, M Cecilia, Lee, Wei-An, Leelarathna, Lalantha, Leiter, Lawrence A, Lind, Marcus, Litchman, Michelle L, Mader, Julia K, Mahoney, Katherine M, Mankovsky, Boris, Masharani, Umesh, Mathioudakis, Nestoras N, Mayorov, Alexander, Messler, Jordan, Miller, Joshua D, Mohan, Viswanathan, Nichols, James H, Nørgaard, Kirsten, O’Neal, David N, Pasquel, Francisco J, Philis-Tsimikas, Athena, Pieber, Thomas, Phillip, Moshe, Polonsky, William H, Pop-Busui, Rodica, Rayman, Gerry, Rhee, Eun-Jung, Russell, Steven J, Shah, Viral N, Sherr, Jennifer L, Sode, Koji, Spanakis, Elias K, Wake, Deborah J, Waki, Kayo, Wallia, Amisha, Weinberg, Melissa E, Wolpert, Howard, Wright, Eugene E, Zilbermint, Mihail, and Kovatchev, Boris

Subjects
Biomedical and Clinical Sciences, Nutrition and Dietetics, Diabetes, Adult, Humans, Blood Glucose, Blood Glucose Self-Monitoring, Hypoglycemia, Hyperglycemia, Glucose, ambulatory glucose profile, composite metric, continuous glucose monitor, diabetes, glycemia risk index, hyperglycemia, hypoglycemia, time in range, Nutrition and dietetics
Abstract

BackgroundA composite metric for the quality of glycemia from continuous glucose monitor (CGM) tracings could be useful for assisting with basic clinical interpretation of CGM data.MethodsWe assembled a data set of 14-day CGM tracings from 225 insulin-treated adults with diabetes. Using a balanced incomplete block design, 330 clinicians who were highly experienced with CGM analysis and interpretation ranked the CGM tracings from best to worst quality of glycemia. We used principal component analysis and multiple regressions to develop a model to predict the clinician ranking based on seven standard metrics in an Ambulatory Glucose Profile: very low-glucose and low-glucose hypoglycemia; very high-glucose and high-glucose hyperglycemia; time in range; mean glucose; and coefficient of variation.ResultsThe analysis showed that clinician rankings depend on two components, one related to hypoglycemia that gives more weight to very low-glucose than to low-glucose and the other related to hyperglycemia that likewise gives greater weight to very high-glucose than to high-glucose. These two components should be calculated and displayed separately, but they can also be combined into a single Glycemia Risk Index (GRI) that corresponds closely to the clinician rankings of the overall quality of glycemia (r = 0.95). The GRI can be displayed graphically on a GRI Grid with the hypoglycemia component on the horizontal axis and the hyperglycemia component on the vertical axis. Diagonal lines divide the graph into five zones (quintiles) corresponding to the best (0th to 20th percentile) to worst (81st to 100th percentile) overall quality of glycemia. The GRI Grid enables users to track sequential changes within an individual over time and compare groups of individuals.ConclusionThe GRI is a single-number summary of the quality of glycemia. Its hypoglycemia and hyperglycemia components provide actionable scores and a graphical display (the GRI Grid) that can be used by clinicians and researchers to determine the glycemic effects of prescribed and investigational treatments.

Published
2023

4. Real-world effectiveness of early insulin therapy on the incidence of cardiovascular events in newly diagnosed type 2 diabetes

Author

Luo, Sihui, Zheng, Xueying, Bao, Wei, Nie, Sheng, Ding, Yu, Yue, Tong, Zhou, Yilun, Hu, Ying, Li, Hua, Yang, Qiongqiong, Wan, Qijun, Liu, Bicheng, Xu, Hong, Li, Guisen, Xu, Gang, Chen, Chunbo, Liu, Huafeng, Shi, Yongjun, Zha, Yan, Kong, Yaozhong, Su, Guobin, Tang, Ying, Gong, Mengchun, Ji, Linong, Hou, Fan Fan, and Weng, Jianping

Published
2024
Full Text
View/download PDF

5. CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

Author

Schnell, Oliver, Barnard-Kelly, Katharine, Battelino, Tadej, Ceriello, Antonio, Larsson, Helena Elding, Fernández-Fernández, Beatriz, Forst, Thomas, Frias, Juan-Pablo, Gavin, III, James R., Giorgino, Francesco, Groop, Per-Henrik, Heerspink, Hiddo J. L., Herzig, Stephan, Hummel, Michael, Huntley, George, Ibrahim, Mahmoud, Itzhak, Baruch, Jacob, Stephan, Ji, Linong, Kosiborod, Mikhail, Lalic, Nebosja, Macieira, Sofia, Malik, Rayaz A., Mankovsky, Boris, Marx, Nikolaus, Mathieu, Chantal, Müller, Timo D., Ray, Kausik, Rodbard, Helena W., Rossing, Peter, Rydén, Lars, Schumm-Draeger, Petra-Maria, Schwarz, Peter, Škrha, Jan, Snoek, Frank, Tacke, Frank, Taylor, Bruce, Jeppesen, Britta Tendal, Tesfaye, Solomon, Topsever, Pinar, Vilsbøll, Tina, Yu, Xuefeng, and Standl, Eberhard

Published
2024
Full Text
View/download PDF

16. Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop

Author

Ceriello, Antonio, Rodbard, Helena W., Battelino, Tadej, Brosius, Frank, Cosentino, Francesco, Green, Jennifer, Ji, Linong, Kellerer, Monika, Koob, Susan, Kosiborod, Mikhail, Lalic, Nebojsa, Marx, Nikolaus, Nedungadi, T. Prashant, Parkin, Christopher G., Rydén, Lars, Sheu, Wayne Huey-Herng, Standl, Eberhard, Vandvik, Per Olav, and Schnell, Oliver

Published
2023
Full Text
View/download PDF

18. CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Author

Schnell, Oliver, Battelino, Tadej, Bergenstal, Richard, Birkenfeld, Andreas L., Ceriello, Antonio, Cheng, Alice, Davies, Melanie, Edelman, Steve, Forst, Thomas, Giorgino, Francesco, Green, Jennifer, Groop, Per-Henrik, Hadjadj, Samy, J.L.Heerspink, Hiddo, Hompesch, Marcus, Izthak, Baruch, Ji, Linong, Kanumilli, Naresh, Mankovsky, Boris, Mathieu, Chantal, Miszon, Martin, Mustafa, Reem, Nauck, Michael, Pecoits-Filho, Roberto, Pettus, Jeremy, Ranta, Kari, Rodbard, Helena W., Rossing, Peter, Ryden, Lars, Schumm-Draeger, Petra-Maria, Solomon, Scott D., Škrha, Jan, Topsever, Pinar, Vilsbøll, Tina, Wilding, John, and Standl, Eberhard

Published
2023
Full Text
View/download PDF

21. Bayesian Optimization Assisted Meal Bolus Decision Based on Gaussian Processes Learning and Risk-Sensitive Control

Author

Cai, Deheng, Liu, Wei, Ji, Linong, and Shi, Dawei

Subjects
Electrical Engineering and Systems Science - Systems and Control
Abstract

Effective postprandial glucose control is important to glucose management for subjects with diabetes mellitus. In this work, a data-driven meal bolus decision method is proposed without the need of subject-specific glucose management parameters. The postprandial glucose dynamics is learnt using Gaussian process regression. Considering the asymmetric risks of hyper- and hypoglycemia and the uncertainties in the predicted glucose trajectories, an asymmetric risk-sensitive cost function is designed. Bayesian optimization is utilized to solve the optimization problem, since the gradient of the cost function is unavailable. The proposed approach is evaluated using the 10-adult cohort of the FDA-accepted UVA/Padova T1DM simulator and compared with the standard insulin bolus calculator. For the case of announced meals, the proposed method achieves satisfactory and similar performance in terms of mean glucose and percentage time in [70, 180] mg/dL without increasing the risk of hypoglycemia. Similar results are observed for the case without the meal information (assuming that the patient follows a consistent diet) and the case of basal rate mismatches. In addition, advisory-mode analysis is performed based on clinical data, which indicates that the method can determine safe and reasonable meal boluses in real clinical settings. The results verify the effectiveness and robustness of the proposed method and indicate the feasibility of achieving improved postprandial glucose regulation through a data-driven optimal control method.

Published
2021

24. Device-supported automated basal insulin titration in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Author

Luo, Yingying, Chang, Yaping, Zhao, Zhan, Xia, Jun, Xu, Chenchen, Bee, Yong Mong, Li, Xiaoying, Sheu, Wayne H.-H., McGill, Margaret, Chan, Siew Pheng, Deodat, Marisa, Suastika, Ketut, Thy, Khue Nguyen, Chen, Liming, Shan Kong, Alice Pik, Chen, Wei, Deerochanawong, Chaicharn, Yabe, Daisuke, Zhao, Weigang, Lim, Soo, Yao, Xiaomei, and Ji, Linong

Published
2023
Full Text
View/download PDF

33. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Author

Schnell, Oliver, Battelino, Tadej, Bergenstal, Richard, Blüher, Matthias, Böhm, Michael, Brosius, Frank, Carr, Richard D., Ceriello, Antonio, Forst, Thomas, Giorgino, Francesco, Guerci, Bruno, Heerspink, Hiddo J. L., Itzhak, Baruch, Ji, Linong, Kosiborod, Mikhail, Lalić, Nebojša, Lehrke, Michael, Marx, Nikolaus, Nauck, Michael, Rodbard, Helena W., Rosano, Giuseppe M. C., Rossing, Peter, Rydén, Lars, Santilli, Francesca, Schumm-Draeger, Petra-Maria, Vandvik, Per Olav, Vilsbøll, Tina, Wanner, Christoph, Wysham, Carol, and Standl, Eberhard

Published
2022
Full Text
View/download PDF

37. Mulberry Twig Alkaloids Improved the Progression of Metabolic-Associated Fatty Liver Disease in High-Fat Diet-Induced Obese Mice by Regulating the PGC1α/PPARα and KEAP1/NRF2 Pathways.

Author

Zhang, Mengqing, Guo, Chengcheng, Li, Zonglin, Cai, Xiaoling, Wen, Xin, Lv, Fang, Lin, Chu, and Ji, Linong

Subjects
FATTY liver, HEPATIC fibrosis, PATHOLOGICAL physiology, INSULIN resistance, LIVER cells, INSULIN
Abstract

Background/Objectives: Metabolic-associated fatty liver disease (MAFLD) is one of the most common liver disorders associated with obesity and metabolic syndrome, and poses a significant global health burden with limited effective treatments. The aim of this study was to assess the protective effects of mulberry twig alkaloids (SZ-A) on MAFLD and to further investigate the underlying mechanisms including the specific targets or pathways. Methods: Diet-induced obesity (DIO) and normal mouse models were established by feeding C57Bl/6J mice with a high-fat diet (HFD) or common diet for 12 weeks. SZ-A, dapagliflozin, and placebo were administered to corresponding mouse groups for 8 weeks. Data of fasting blood glucose, glucose tolerance, insulin tolerance, and the body weight of mice were collected at the baseline and termination of the experiment. Serum liver enzymes and lipids were measured by ELISA. Western blotting, qPCR, and pathological section staining were implemented to evaluate the degrees of liver steatosis, fibrosis, and oxidative stress in mice. Results: In DIO mouse models, high-dose SZ-A (800 mg/kg/d) treatment significantly inhibited HFD-induced weight gain, improved insulin tolerance, and reduced serum alanine aminotransferase, total cholesterol, and triglyceride levels compared with placebo. In DIO mice, SZ-A could alleviate the pathological changes of hepatic steatosis and fibrosis compared with placebo. Lipid catabolism and antioxidant stress-related proteins were significantly increased in the livers of the high-dose SZ-A group (p < 0.05). Inhibition of PGC1α could inhibit the function of SZ-A to enhance lipid metabolism in hepatocytes. PGC1α might interact with NRF2 to exert MAFLD-remedying effects. Conclusions: By regulating the expression of PGC1α and its interacting KEAP1/NRF2 pathway in mouse liver cells, SZ-A played important roles in regulating lipid metabolism, inhibiting oxidative stress, and postponing liver fibrosis in mice with MAFLD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. CVOT Summit Report 2023:new cardiovascular, kidney, and metabolic outcomes

Author

Schnell, Oliver, Barnard-Kelly, Katharine, Battelino, Tadej, Ceriello, Antonio, Larsson, Helena Elding, Fernández-Fernández, Beatriz, Forst, Thomas, Frias, Juan Pablo, Gavin, James R., Giorgino, Francesco, Groop, Per Henrik, Heerspink, Hiddo J.L., Herzig, Stephan, Hummel, Michael, Huntley, George, Ibrahim, Mahmoud, Itzhak, Baruch, Jacob, Stephan, Ji, Linong, Kosiborod, Mikhail, Lalic, Nebosja, Macieira, Sofia, Malik, Rayaz A., Mankovsky, Boris, Marx, Nikolaus, Mathieu, Chantal, Müller, Timo D., Ray, Kausik, Rodbard, Helena W., Rossing, Peter, Rydén, Lars, Schumm-Draeger, Petra Maria, Schwarz, Peter, Škrha, Jan, Snoek, Frank, Tacke, Frank, Taylor, Bruce, Jeppesen, Britta Tendal, Tesfaye, Solomon, Topsever, Pinar, Vilsbøll, Tina, Yu, Xuefeng, Standl, Eberhard, Schnell, Oliver, Barnard-Kelly, Katharine, Battelino, Tadej, Ceriello, Antonio, Larsson, Helena Elding, Fernández-Fernández, Beatriz, Forst, Thomas, Frias, Juan Pablo, Gavin, James R., Giorgino, Francesco, Groop, Per Henrik, Heerspink, Hiddo J.L., Herzig, Stephan, Hummel, Michael, Huntley, George, Ibrahim, Mahmoud, Itzhak, Baruch, Jacob, Stephan, Ji, Linong, Kosiborod, Mikhail, Lalic, Nebosja, Macieira, Sofia, Malik, Rayaz A., Mankovsky, Boris, Marx, Nikolaus, Mathieu, Chantal, Müller, Timo D., Ray, Kausik, Rodbard, Helena W., Rossing, Peter, Rydén, Lars, Schumm-Draeger, Petra Maria, Schwarz, Peter, Škrha, Jan, Snoek, Frank, Tacke, Frank, Taylor, Bruce, Jeppesen, Britta Tendal, Tesfaye, Solomon, Topsever, Pinar, Vilsbøll, Tina, Yu, Xuefeng, and Standl, Eberhard

Abstract

The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technolo, The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) techn

Published
2024

46. Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study

Author

Ji, Linong, Du, Ying, Xu, Min, Zhou, Xiangjun, Mo, Zhaohui, Ma, Jianhua, Li, Jiarui, Li, Yufeng, Lin, Jingna, Wang, Yanjun, Yang, Jing, Song, Weihong, Jin, Hui, Pang, Shuguang, Liu, Hui, Li, Ping, Liu, Jie, Yao, Minxiu, Li, Wenhui, Jiang, Xiaohong, Shen, Feixia, Geng, Houfa, Zhou, Haifeng, Ran, Jianmin, Lei, Minxiang, Du, Yinghong, Ye, Shandong, Guan, Qingbo, Lv, Wenshan, Tan, Huiwen, Chen, Tao, Yang, Jinkui, Qin, Guijun, Li, Shiyun, and Chen, Lei

Published
2021
Full Text
View/download PDF

48. Insulin titration and blood glucose fluctuations during pregnancy in GCK-MODY: Case Report.

Author

Zhao, Yilin, Ba, Tianhao, Ren, Qian, Han, Xueyao, and Ji, Linong

Subjects
INSULIN therapy, BLOOD sugar analysis, FETAL growth retardation, MATURITY onset diabetes of the young, PREGNANCY outcomes, GENETIC mutation, FETAL development, AMNIOCENTESIS, GENETIC testing, HYPOGLYCEMIA, DISEASE risk factors, PREGNANCY
Abstract

Background: Glucokinase-maturity onset diabetes of the young (GCK-MODY) is a form of monogenic diabetes that is caused by heterozygous inactivating mutations in GCK gene. The management of GCK-MODY during pregnancy is challenging, as pharmacological treatment dose could not alter glycaemia in GCK-MODY in longitudinal studies and noninvasive antenatal fetal GCK genotyping is unavailable. Case presentation: Here, we report a case of GCK-MODY with pregnancy. The patient was 41 years old. She was diagnosed with GCK-MODY at 10 weeks of gestation. At 22 weeks and 6 days of gestation, she underwent amniocentesis due to her advanced age and genetic testing confirmed that the fetus was a heterozygous mutation carrier. We described the characteristics of blood glucose fluctuation, insulin responsiveness, hypoglycemic risk, fetal development, and pregnancy outcome before and after fetus genetic testing during her entire pregnancy. Until now, there were no studies describing insulin titration and blood glucose fluctuations during pregnancy in patients with GCK-MODY. Conclusion: Our case indicted that insulin therapy during pregnancy is effective in GCK-MODY. Careful dietary modifications, individualized insulin titration and specialized diabetes education can reduce the risk of hypoglycemia and improve gestational outcome in GCK-MODY with pregnancy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results